Gold prices steady as traders assess Fed rate outlook after soft US data
Investing.com - Lipocine reported on Wednesday third quarter earnings that matched analysts' forecasts and revenue that fell short of expectations.
Lipocine announced earnings per share of $-0.0300 on revenue of $600K. Analysts polled by Investing.com EPS of $-0.0300 on revenue of $798.67K.
Lipocine 's are down 28.9% and is trading at $0.3666 , still down 80.60% from its 52 week high of $1.89 set on Friday, March 25, 2022.
Lipocine shares lost 6.24% to trade at $0.3666 in intra-day trade the report.
Lipocine follows other major Healthcare sector earnings this month
Lipocine's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar